Huaige Capital has closed its third RMB-denominated fund at over 300 million yuan ($43 million), as the three-year-old investment firm steps up efforts to make the most of China’s fast-growing healthcare sector.
The fund, Huaige Ruixin, which was kicked off in March this year, received “strong subscription demand” from investors and raised enough capital commitments in April despite the headwinds caused by the coronavirus pandemic, Wang Kai, founding partner, Huaige Capital, told DealStreetAsia.
